Table IV.
Low income | Lower middle income | Upper middle income | All | ||
---|---|---|---|---|---|
|
|||||
Base case | Mean | 839 | 1,246 | 2,783 | 1,494 |
Median | 792 | 932 | 1,454 | 1,005 | |
SD | 175 | 1,546 | 2,500 | 1,628 | |
Min | 682 | 156 | 1,230 | 156 | |
Max | 1,089 | 3,904 | 5,667 | 5,667 | |
Countries | 4 | 5 | 3 | 12 | |
Studies (N) | 6 | 7 | 13 | 26 | |
Data points/sites (n) | 10 | 12 | 24 | 45 | |
|
|||||
1. Weighing all study sites, instead of all countries equally | Mean | 770 | 714 | 2,366 | 1,600 |
Median | 797 | 298 | 1,397 | 1,077 | |
SD | 226 | 1,067 | 2 | 1,772 | |
Min | 263 | 97 | 522 | 97 | |
Max | 1,089 | 3,904 | 7,688 | 7,688 | |
Countries | 4 | 5 | 3 | 12 | |
Studies (N) | 6 | 7 | 13 | 26 | |
Data points/sites (n) | 10 | 12 | 24 | 46 | |
|
|||||
2. Adding studies reporting total unit cost without ARV/lab/HR break-down | Mean | 713 | 1,314 | Unchanged from base-case | 1,422 |
Median | 773 | 932 | 932 | ||
SD | 319 | 1,637 | 1,639 | ||
Min | 211 | 162 | 162 | ||
Max | 1,089 | 4,212 | 5,667 | ||
Countries | 5 | 5 | 13 | ||
Studies (N) | 7 | 9 | 29 | ||
Data points/sites (n) | 11 | 14 | 48 | ||
|
|||||
3. Country income level according to costing year | Mean | 565 | 1,683 | 3,068 | 1,496 |
Median | 646 | 1,454 | 1,241 | 1,073 | |
SD | 346 | 886 | 2,537 | 1,559 | |
Min | 97 | 522 | 1,068 | 156 | |
Max | 1,089 | 3,904 | 7,688 | 5,667 | |
Countries | 7 | 4 | 2 | 12 | |
Studies (N) | 11 | 9 | 6 | 26 | |
Data points/sites (n) | 20 | 13 | 13 | 45 |
Notes: The base case aggregates total ART unit costs per person per year (in 2009 USD) by first taking the median within each country. Sensitivity analyses are as follows: 1. All study sites weighted equally, regardless of country or number of sites per country. 2) Expanded dataset to include studies which did not include a break-down of cost components, but had data on total ART costs. 3) Use World Bank GNI per capita data at the time of the study costing, instead of 2009 GNI, to classify countries according to income level. Baseline estimates based on more than 14,765 patients from 26 studies, plus additional studies that did not disaggregate costs by cost component. Twelve studies specifically reported costs for first-line treatment; one study [39] specifically included second-line treatment but those specific costs were excluded. Total data points aggregate to 45 because two studies from Mexico [37, 38] were considered as only one data point as they referred to the same study population, but we needed both sources to obtain all the necessary information. See tables I, II, and III, text and annexes for further details.